Barclays Issues Positive Forecast for Agilent Technologies (NYSE:A) Stock Price

Agilent Technologies (NYSE:A) had its price target upped by Barclays from $125.00 to $150.00 in a research note issued to investors on Thursday,Benzinga reports. Barclays currently has an equal weight rating on the medical research company’s stock.

A has been the subject of several other research reports. Wall Street Zen cut Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Friday, September 5th. Wells Fargo & Company lifted their price objective on Agilent Technologies from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Monday, September 15th. Evercore ISI cut their price target on Agilent Technologies from $130.00 to $128.00 and set an “in-line” rating for the company in a report on Thursday, August 28th. Finally, Robert W. Baird boosted their price objective on Agilent Technologies from $141.00 to $142.00 and gave the company an “outperform” rating in a research report on Thursday, August 28th. Six research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $142.17.

Agilent Technologies Trading Up 0.1%

A opened at $138.66 on Thursday. The stock has a market cap of $39.31 billion, a PE ratio of 32.55, a PEG ratio of 4.52 and a beta of 1.26. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. The business has a 50 day moving average of $122.36 and a 200-day moving average of $116.28. Agilent Technologies has a 52 week low of $96.43 and a 52 week high of $153.84.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.37. The business had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The firm’s quarterly revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities research analysts predict that Agilent Technologies will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 22nd. Investors of record on Tuesday, September 30th will be issued a $0.248 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $0.99 dividend on an annualized basis and a yield of 0.7%. Agilent Technologies’s dividend payout ratio is currently 23.24%.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Brighton Jones LLC raised its position in Agilent Technologies by 6.1% in the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock valued at $626,000 after purchasing an additional 270 shares during the period. NBC Securities Inc. raised its position in Agilent Technologies by 113,700.0% in the first quarter. NBC Securities Inc. now owns 2,276 shares of the medical research company’s stock valued at $266,000 after purchasing an additional 2,274 shares during the period. Merit Financial Group LLC raised its position in Agilent Technologies by 56.3% in the first quarter. Merit Financial Group LLC now owns 4,348 shares of the medical research company’s stock valued at $509,000 after purchasing an additional 1,567 shares during the period. Whipplewood Advisors LLC increased its position in shares of Agilent Technologies by 286.2% during the first quarter. Whipplewood Advisors LLC now owns 251 shares of the medical research company’s stock worth $29,000 after acquiring an additional 186 shares during the period. Finally, Naples Global Advisors LLC increased its position in shares of Agilent Technologies by 13.1% during the first quarter. Naples Global Advisors LLC now owns 17,900 shares of the medical research company’s stock worth $2,094,000 after acquiring an additional 2,080 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.